Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia

Asian Journal of Psychiatry
Rashmin M AchaliaOm Prakash

Abstract

Tardive dyskinesia (TD) is one of the most distressing side effects of antipsychotic treatment. As prevalence studies of TD in Asian population are scarce, a cross-sectional study was performed to assess the frequency of TD in Indian patients with schizophrenia and risk factors of TD. Cross-sectional study of 160 Indian patients fulfilling the DSM-IV TR criteria for schizophrenia and who received antipsychotics for at least one year, were examined with two validated scales for TD. Logistic regression analyses were used to examine the relationship between TD and clinical risk factors. The frequency of probable TD in the total sample was 26.4%. The logistic regression yielded significant odds ratios between TD and age, intermittent treatment, and total cumulative antipsychotic dose. The difference of TD between SGA and FGA disappeared after adjusting for important co-variables in regression analysis. Indian patients with schizophrenia and long-term antipsychotic treatment have a high risk of TD, and TD is associated with older age, intermittent antipsychotic treatment, and a high total cumulative antipsychotic dose. Our study findings suggest that there is no significant difference between SGAs with regards to the risk of causing...Continue Reading

References

Oct 1, 1992·Acta Psychiatrica Scandinavica·R Yassa, N P Nair
Jan 1, 1991·European Archives of Psychiatry and Clinical Neuroscience·T InadaY Masuda
Nov 6, 1991·JAMA : the Journal of the American Medical Association·B L SaltzK Kahaner
Jan 1, 1985·Progress in Neuro-psychopharmacology & Biological Psychiatry·W GuyW H Wilson
Jan 1, 1973·The American Journal of Psychiatry·H L Klawans
Dec 1, 1980·Archives of General Psychiatry·J M Smith, R J Baldessarini
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, John M Kane
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·G Chouinard, S Steinberg
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·H ItohK Ogita
Sep 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·W GreilE Rüther
Jan 1, 1995·European Archives of Psychiatry and Clinical Neuroscience·A K Pandurangi, Y A Aderibigbe
Apr 18, 1998·The American Journal of Psychiatry·Peter N van HartenR S Kahn
Jan 27, 1999·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·D V JesteJ Lacro
Apr 22, 1999·The British Journal of Psychiatry : the Journal of Mental Science·C M BeasleyGary D Tollefson
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Siu-Kau LeungTony Leung
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Martin R K DossenbachOlanzapine HGCH Study Group
Feb 25, 2005·International Clinical Psychopharmacology·Ya-Mei BaiChao-Cheng Lin
Oct 24, 2007·Acta Psychiatrica Scandinavica. Supplementum·E LindströmS Levander
Apr 7, 2009·Parkinsonism & Related Disorders·Criscely L GoHubert H Fernandez
Aug 1, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Diederik E TenbackJim van Os

Citations

Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
Aug 28, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Joshua ListerGary Remington
Feb 19, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Pierre J Blanchet, Daniel Lévesque
Jul 7, 2020·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre J Blanchet
Jan 15, 2019·Current Medical Research and Opinion·Joseph McEvoyBenjamin Carroll
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N Caroff
Dec 22, 2020·Behavioural Brain Research·Alice ServonnetAnne-Noël Samaha
Dec 10, 2020·Clinical Pharmacology : Advances and Applications·Assefa KumsaLiyew Agenagnew

Related Concepts

Prevalence Studies
Dyskinesia, Medication-Induced
Schizophrenia
Antipsychotic Effect
Comorbidity
Cross-Sectional Studies
Dyskinetic Syndrome
Schizophrenia
Antipsychotic Agents
Asians

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here